secwatch.observer — SEC 8-K summary
======================================

Issuer:     Repare Therapeutics Inc. (—)
CIK:        0001808158
Form:       8-K
Filed at:   2026-01-28T23:59:59+00:00
Accession:  0001193125-26-027394
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repare Therapeutics acquired by XenoTherapeutics for ~$2.20/sh plus CVR
-----------------------------------------------------------------------

- Completion of acquisition by XenoTherapeutics; shareholders received ~$2.20 per share in cash plus one CVR per share.
- Transaction approved by shareholders on Jan 16, 2026; court order obtained Jan 23, 2026.
- Common shares to cease trading on Nasdaq on/about Jan 28, 2026; Form 15 to be filed to suspend reporting obligations.
- All directors resigned; Jon Adkins (sole director of Purchaser) becomes sole director and officer of surviving corporation.
- Contingent value rights (CVR) represent right to receive pro rata portion of potential future cash payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808158/000119312526027394/0001193125-26-027394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808158/000119312526027394/d95398d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-027394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer